Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells 7,879 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 7,879 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $348,330.59. Following the sale, the chief operating officer now owns 18,672 shares of the company’s stock, valued at approximately $825,489.12. This trade represents a 29.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Peter Radovich also recently made the following trade(s):

• On Monday, February 3rd, Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $48.22, for a total transaction of $126,673.94.
• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total value of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $85,554.36.

Mirum Pharmaceuticals Stock Down 1.9 %

MIRM opened at $44.31 on Wednesday. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $54.23. The firm has a 50 day moving average price of $47.55 and a 200 day moving average price of $43.60. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The company has a market cap of $2.17 billion, a PE ratio of -21.94 and a beta of 1.04.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million. Sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on MIRM shares. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, February 27th. HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $58.20.

Institutional Trading of Mirum Pharmaceuticals

Several large investors have recently bought and sold shares of MIRM. GF Fund Management CO. LTD. acquired a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Mirum Pharmaceuticals by 16.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company’s stock valued at $3,055,000 after purchasing an additional 10,427 shares in the last quarter. Woodline Partners LP increased its stake in Mirum Pharmaceuticals by 22.2% during the 4th quarter. Woodline Partners LP now owns 404,404 shares of the company’s stock worth $16,722,000 after buying an additional 73,399 shares during the period. Squarepoint Ops LLC acquired a new position in Mirum Pharmaceuticals in the 4th quarter worth $897,000. Finally, Tema Etfs LLC purchased a new position in Mirum Pharmaceuticals in the 4th quarter valued at about $1,735,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.